PETALING JAYA: A new affordable hepatitis C treatment will soon be introduced in Malaysia, making it possible for patients to receive treatment for the potentially fatal disease.
Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd (Pharmaniaga) had on Monday signed an agreement with Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit organization Drugs for Neglected Diseases initiative (DNDi) to supply a new hepatitis C treatment regimen that will be sold for about US$300 (RM1,256.83).
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
